One of the many aggressive and worst types of cancer is neuroendocrine carcinoma of colon. The worst thing about this is that it’s most frequently detected at the advanced stages at which time it is more difficult to curb it and treat it.
As the symptoms of neuroendocrine colon cancer become visible only in the most advanced stages the rate of survival of the patient diminishes. The tumors are always malignant, and mostly detected with distant metastases. Most recent surveys show that reports tell us that in almost all cases of neuroendocrine cancer end with the death of the patient.
Though the possibilities of neuroendocrine carcinoma in colon are very rare, if unfortunately one is affected by this disease, the health of the patient becomes worse than patients who suffer from adenocarcinoma.
Research reveals that the final results of this cancer stay the same with age, sex or tumor location. Though neuroendocrine colon carcinoma depends on which stage the tumor is in The usual trends reveal that most peopleshow that generally people in stage 1 and 2 of cancer usually do not suffer from neuroendocrine colon cancer. But alternately in the majority of cases if the tumor is in stage 3 or 4, it is a laborious and hard task the neuroendocrine colon carcinoma.
Sadly, medical science has developed no adequate methods to deal with this particular cancer. A more common technique that doctors might use is immunohistochemical staining methods. This method helps doctors in dealing with the seriousness of neuroendocrine colon cancer and helps to determine the most helpful medication and a way to treat it. Immunohistochemical staining methods is specifically used for neuroendocrine markers. This involves staining of the tumor with a monoclonal antibody A-80 which helps in identifying the quantum of neuroendocrine differentiation and the extent of damage caused to the health.
Neuroendocrine colon carcinoma is cumbersome to deal with and a case study where several patients suffered from colon carcinoma were examined, it was observed that the average survival rate for this disease was only about seven months. While in a predominant stage, these rates decrease, to as low as five months or less. The great majority of these cases were originally seen as carcinoids but they soon became in to neuroendocrine colon carcinoma. Neuroendocrine colon cancer has a bad prognosis and surgery may not be a perfect or even viable treatment so surgery may not even cure the patient. So this makes it important to notice the presence of this disease on time and provide proper medication for it.